Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Jpn J Clin Oncol
Hauptverfasser: Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2015
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412139/
https://ncbi.nlm.nih.gov/pubmed/25647781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv011
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge